European Journal of Biomedical and Pharmaceutical Sciences

IS METFORMIN AND VILDAGLIPTIN COMBINATION BETTER THAN METFORMIN AND GLIMEPIRIDE COMBINATION FOR THE MANAGEMENT OF TYPE II DIABETES?

Sapan Shah, Rumana Tokaria, Milan Gajera, Tapan Miyani, Milisha Lal, Rushin Patel Gagan Anand, Parvinder Aulakh, Harsh Chapadia and Abhishek Vadher*

ABSTRACT

Background: In this study, we compared the efficacy and the adverse events of a combination of Metformin-Vildagliptin and Metformin- Glimepiride. Methods: During this study, a total of 248 patients who were diagnosed with type II Diabetes Mellitus were taken. The 118 cases were Metformin combined with Vildagliptin and 126 cases were given Metformin combined with Glimepiride. HbA1c was measured at 3 months after the initiation of the treatment. Results: The reduction of HbA1c in Metformin + Vildagliptin group was 1.23 ±0.43 and in Metformin + Glimepiride group was 1.12±0.68. This showed that the reduction in HbA1c in both the groups was comparable. Hypoglycemia was more in Metformin + Glimepiride group than the Metformin + Vildagliptin group (p value=0.0001).Other adverse events were not statistically significant. Conclusion: The combination of Metformin and Vildagliptin had similar outcomes in reducing HbA1c and similar adverse events when compared to Metformin and Glimepiride, but hypoglycemic events were more common later. Therefore, Metformin and Vildagliptin combination is better than Metformin and Glimepiride combination for the management of type II Diabetes

Keywords: In this study, we compared Metformin + Vildagliptin type II Diabetes.